Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial.

MLA

Ward, Leanne M., et al. “Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-Induced Osteoporosis: A Randomized, Double-Blind, Phase 3 Trial.” Journal of Clinical Endocrinology & Metabolism, vol. 106, no. 12, Dec. 2021, pp. e522–5235. EBSCOhost, https://doi.org/10.1210/clinem/dgab458.

APA

Ward, L. M., Choudhury, A., Alos, N., Cabral, D. A., Rodd, C., Sbrocchi, A. M., Taback, S., Padidela, R., Shaw, N. J., Hosszu, E., Kostik, M., Alexeeva, E., Thandrayen, K., Shenouda, N., Jaremko, J. L., Sunkara, G., Sayyed, S., Aftring, R. P., & Munns, C. F. (2021). Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial. Journal of Clinical Endocrinology & Metabolism, 106(12), e522–e5235. https://doi.org/10.1210/clinem/dgab458

Chicago

Ward, Leanne M., Anup Choudhury, Nathalie Alos, David A. Cabral, Celia Rodd, Anne Marie Sbrocchi, Shayne Taback, et al. 2021. “Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-Induced Osteoporosis: A Randomized, Double-Blind, Phase 3 Trial.” Journal of Clinical Endocrinology & Metabolism 106 (12): e522–5235. doi:10.1210/clinem/dgab458.